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• A negative HPV results at baseline predicts one-half the risk of CIN3+ over 3 years than a negative cytology result.
• HPV primary screening with triage using 16/18 genotyping and cytology increases sensitivity to detect CIN3+ 28% over cytology.
• Cytology failed to detect approximately 50% of CIN3+ in women 25–29 years.☆ This study is registered with ClinicalTrials.gov (NCT00
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Objectives. ATHENA evaluated the cobas HPV Test as the primary screen for cervical cancer in women ≥25
years. This reports the 3-year end-of-study results comparing the performance of HPV primary screening to
different screening and triage combinations.
Methods.42,209women≥25 yearswere enrolled andhad cytology andhrHPV testing.Womenwith abnormal
cytology (≥atypical squamous cells of undetermined signiﬁcance) and those HPV positive were referred to
colposcopy. Women not reaching the study endpoint of CIN2+ entered the 3-year follow-up phase.
Results.3-year CIR of CIN3+ in cytology-negativewomenwas 0.8% (95% CI; 0.5–1.1%), 0.3% (95%CI 0.1–0.7%)
in HPV-negative women, and 0.3% (95% CI; 0.1–0.6%) in cytology and HPV negative women. The sensitivity
for CIN3+of cytologywas 47.8% (95%CI; 41.6–54.1%) compared to 61.7% (95%CI; 56.0–67.5%) for the hybrid strat-
egy (cytology if 25–29 years and cotestingwith cytology andHPV if≥30 years) and76.1% (95% CI; 70.3–81.8%) for
HPV primary. The speciﬁcity for CIN3+ was 97.1% (95% CI; 96.9–97.2%), 94.6% (95% CI; 94.4–94.8%), and 93.5%
(95% CI; 93.3–93.8%) for cytology, hybrid strategy, andHPV primary, respectively. AlthoughHPV primary detects sig-
niﬁcantlymore cases of CIN3+ inwomen≥25 years than either cytologyor hybrid strategy, it requires signiﬁcantly
more colposcopies. However, the number of colposcopies required to detect a single CIN3+ is the same as for the
hybrid strategy.
Conclusions.HPVprimary screening inwomen≥25 years is as effective as a hybrid screening strategy that uses
cytology if 25–29 years and cotesting if≥30 years. However, HPV primary screening requires less screening tests.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Persistent infection with a high-risk human papillomavirus (HPV)
genotype is required for the development of high-grade cervical709891).
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. This is an open access article underneoplasia (cervical intraepithelial neoplasia [CIN] grade 3, adenocarci-
noma in-situ, and invasive cervical cancer (CIN3+) [1]. Molecular
tests that detect HPV demonstrate increased sensitivity but lower spec-
iﬁcity than cytology for detecting women with CIN3+ [2]. Currently in
the United States (U.S.) HPV testing is recommended to triage women
with atypical squamous cells of undetermined signiﬁcance (ASC-US)
and as an adjunct to cytology when screening women ≥30 years
(i.e., “cotesting”) [3–5]. In Europe, guidelines recommend the use of
HPV testing to triage women with ASC-US, for surveillance after treat-
ment of CIN, and as a stand-alone primary screening testwithout cytologythe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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tries including Australia and the Netherlands have now adopted HPV pri-
mary screening for their national screening programs [7,8]. HPV primary
screening could reduce both the complexities and resource expenditure
inherent in cotesting while maintaining a high sensitivity. Longitudinal
follow-up studies and randomized trials have shown that HPV primary
screening is more sensitive than cytology and identiﬁes CIN3+ earlier
[2,9]. As a result, fewer cases of cervical cancer or CIN3 are identiﬁed on
subsequent rounds of screening [10,11]. Despite the attractiveness of
HPV primary screening, there remain several unresolved issues. These in-
clude developing an effective strategy to determine which HPV-positive
women shouldbe referred to colposcopy andhowHPVprimary screening
performs in the U.S.
In 2008, the 3-year prospective ATHENA (Addressing the Need for
Advanced HPV Diagnostics) study was initiated in the U.S. [12]. This
study was speciﬁcally designed to evaluate primary screening with
the cobas HPV test inwomen≥25 years in theU.S. aswell as to evaluate
different triage strategies for HPV-positivewomen. End-of-study results
from ATHENA are presented in this manuscript.
Materials and methods
Study patients
Nonpregnant U.S. women ≥21 years presenting for routine cervical
cancer screening (n=47,208)were enrolled in this observational study
between May 2008 and August 2009. Study inclusion and exclusion
criteria have been previously described and are provided in detail in
the Supplemental appendix together with an in-depth description of
study procedures [12–14]. Since current U.S. management guidelines
recommend against HPV testing for any reason below the age of 25
years, only women ≥25 years were included in the 3-year follow-up
phase and in this subanalysis (n = 41,955) [5]. The study protocol
was approved by institutional review boards of all study sites, and
written informed consent was obtained. This study is registered with
ClinicalTrials.gov (NCT00709891) and was completed in December
2012.
Design and study interventions
Baseline phase
After a brief medical history, a cervical sample was collected
and placed into a PreservCyt vial (Hologic, Inc.). Prior to processing for
cytology (ThinPrep; Hologic, Inc), a 4-mL aliquot was removed for
HPV testing using the cobas HPV Test (Roche Molecular Systems) that
provides three HPV positive/negative results: HPV 16, HPV 18, and 12
other HPV genotypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 66,
pooled). Samples were also tested using the AMPLICOR and LINEAR
ARRAY HPV Genotyping Test (Roche Molecular Systems) which are re-
search tests with high analytic sensitivities. Cytology and HPV testing
were conducted in the U.S. at 4 clinical laboratories and Roche Molecu-
lar Systems served as a ﬁfth site for HPV testing. Bethesda System termi-
nologywas used for reporting cytology results [15]. Prior to reporting to
the sites, test results were entered into a randomization database that
selected women for colposcopy based on age, cytology and
AMPLICOR/LINEAR ARRAY HPV test results. This included all women
with abnormal cytology and HPV positivity, as well as a random subset
of HPV and cytology-negative women that was required for veriﬁcation
bias adjustment of the performance of the screening tests.
Colposcopywith biopsy and in some patients endocervical curettage
(ECC) was completed within 12 weeks of the initial visit (see Supple-
mental appendix for complete details). Both the colposcopist and
patients weremasked to the screening test results until after the colpos-
copy visit. Biopsies and ECCs were reviewed by a panel of 3 pathologists
who were masked to patient information and screening test results.Standard CIN terminology was used for reporting the histology results
[16].Womenwith CIN2+exited the study for appropriatemanagement.
Follow-up phase
All women who underwent colposcopy in the baseline phase and
who did not have CIN2+ were eligible for the 3-year follow-up phase.
During follow-up, women had annual examinations with collection
of a cervical specimen for both cytology and HPV testing. Women with
abnormal cervical cytology (≥ASC-US) underwent colposcopy with
biopsies and ECCs that were reviewed as in the baseline phase. Women
diagnosed with CIN2+ during follow-up exited the study. At year 3, pa-
tients were invited to have an “exit colposcopy” (see Supplemental ap-
pendix for complete details). Women who declined the exit colposcopy
(319 of 4663) had a cervical specimen collected for cytology and HPV
testing.
Primary and secondary outcomes
The follow-up phase of ATHENA was designed to document the
safety of the cobas HPV Test both when used for cotesting in women
≥30 years as well as when used for HPV primary screening in U.S.
women ≥25 years. With respect to primary HPV screening in women
≥25 years, the 3-year follow-up phase had two secondary objectives.
The ﬁrst was to compare the 3-year cumulative risk of CIN2+ in
women with different baseline HPV results (stratiﬁed by HPV negative,
pooled 14 high-risk HPV positive, HPV 16/18 positive, and HPV 12
“other” positive). The second objective was to compare the 3-year cu-
mulative incidence rate of CIN2+ in women with a negative HPV test
at baseline and those with a negative cytology. After analyzing the per-
formance of different screening strategies incorporating HPV testing
alone and in combination with cytology for the detection of CIN2+
using data from the baseline phase, we decided to perform a post hoc
analysis of the performance of these strategies over the full 3 years of
the study. This was indicated because all of the strategies incorporate
retesting of selected women at 12 months and it was important to in-
clude the results of this retesting to fully understand how the strategies
would perform in a screening setting [5,17].
Screening strategies
We calculated the performance of three screening strategies for
women enrolled in ATHENA over a 3-year period using the dataset
created by the study. One strategy was cytology with HPV testing per-
formed only for ASC-US (cytology). The second was a hybrid strategy
that uses the cytology strategy for women 25–29 years of age and
cotesting with both cytology and HPV (pooled 14 genotypes) in
women ≥30 years. The hybrid strategy mimics current U.S. screening
recommendations [3,4]. With cotesting, HPV-positive women with
negative cytology are retested with both tests in 1 year and undergo
colposcopy if either is abnormal. We compared these strategies with a
HPV primary strategy in which HPV-negative women are rescreened in
3 years, HPV16/18-positive women receive colposcopy, and women
positive for the 12 other HPV genotypes have reﬂex cytology with
colposcopy if the cytology is ≥ASC-US. If the cytology is negative
women are rescreenedwithHPV and cytology in 1 year. In all strategies,
womenwhowere referred to colposcopy and found to not have CIN2+
are rescreened with both tests in 1 year and referred to colposcopy if
≥ASC-US or persistently HPV-positive. More complete details of the
screening strategies are provided in the Supplemental appendix.
Statistical analysis
Veriﬁcation bias adjusted (VBA) estimates of absolute risk of CIN2+
or CIN3+ for each year were obtained by estimating the likely cases of
CIN2+ and bCIN2 for each year as previously described [13,14]. Cumu-
lative risk over 3 yearswas obtained by using the Kaplan–Meiermethod
and the VBA risk estimates for each year. Conﬁdence intervals for the
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depth description of how the calculations were adjusted for selection
bias and loss to follow-up is included in the Supplemental appendix.
Calculating 3-year performance of screening strategies
Because cytology and HPV testing were performed each year during
the study, we could determine HPV persistence, repeat cytology results,
and loss to follow-up rates annually. This allowed calculation of how
speciﬁc screening strategies would perform over the course of 3 years,
as well as the utilization of clinical resources to include number of
tests, colposcopies and number of colposcopies required to detect one
case of CIN2+.
Since all women who were HPV-positive or had ≥ASC-US at base-
line underwent colposcopy and exited the study if they had CIN2+,
calculating how individual screening strategies would perform over a
3-year screening cycle required 3 assumptions. One was that CIN2+
lesions identiﬁed at the baseline colposcopy but missed by a speciﬁc
screening strategy would persist until the Year 1 visit and be detected
if the woman was referred to colposcopy based on the Year 1 cytology
and HPV results. The second was that HPV-positive CIN2+ lesions at
baseline would be persistently HPV positive at Year 1. Finally, we
assumed that any woman who returned for follow-up and had an ab-
normal test result underwent colposcopy. A more detailed description
of how the calculations were adjusted for selection bias and loss to
follow-up is included in the Supplemental appendix.
Results
From May 2008 to August 2009, 42,209 women ≥25 years were
enrolled in ATHENA, of whom 41,955 (99%) met the eligibility criteria.
The baseline demographic characteristics of this population have been
previously described and are provided in Supplemental appendix [13].
A total of 1054women hadmissing or invalid test results at enrollment,
leaving 40,901 women evaluable for this analysis. After the enrollment
visit, 9353 women were selected for colposcopy, of whom 8067 had
the procedure (Fig. 1A). This included 892 randomly assigned women
who were both HPV and cytology-negative allowing for adjustment of
veriﬁcation bias. The follow-up rates were 81%, 84% and 90% for years
1, 2 and 3, respectively (Fig. 1B). During the course of the 3-year study
a total of 240 CIN2, 319 CIN3, 20 adenocarcinoma in-situ, and 8 invasive
cervical cancer cases were detected, Supplemental appendix.
3-year cumulative risk of CIN3+ (or CIN2+)
At baseline 10.5% (4275 of 40,901) ofwomenwereHPV-positive and
6.4% (2617 of 40,901) had cytology of ≥ASC-US. 164 of 347 (47.3%) of
CIN3+ identiﬁed during the 3-year study occurred inwomenwith neg-
ative baseline cytology, Supplemental appendix. In contrast, 34 (9.8%)
occurred in women high risk HPV negative at baseline (p b 0.001).
Similar results were observed using a CIN2+ endpoint. All of the inva-
sive cervical cancers (8 of 8) were HPV-positive at baseline, and 7 of
8 (87.5%) had ≥ASC-US cytology. 6 of 8 (75%) cervical cancers were
identiﬁed at the baseline colposcopy and 2 (25%) at Year 1 colposcopy.
Of 20 cases of adenocarcinoma in-situ, 17 (85.0%) were HPV-positive
at baseline and 13 (65.0%) had ≥ASC-US.
HPV genotype status at baseline was predictive for CIN3+ (or
CIN2+) during the course of the study (Fig. 2). CIN3+ was identiﬁed
at baseline in 17.8% (95% CI, 14.8–20.7%) of HPV16 positive women
and after 3 years the cumulative incidence rate (CIR) was 25.2%
(95% CI, 21.7–28.7%). In contrast, the 3-year CIR of CIN3+ was 5.4%
(95% CI, 4.5–6.3%) in women with HPV genotypes other than 16/18.
HPV18positivewomenhad a 3-year CIR thatwas intermediate between
women with HPV16 and women with 12 other genotypes. Similar re-
sults were observed using a CIN2+ endpoint. Fig. 3 presents the VBA
3-year CIR for all of the different combinations of baseline screening
test results. The 3-year CIR for CIN3+ was lower in HPV-negativewomen (0.3%; 95% CI, 0.1–0.7%) than in cytology-negative women
(0.8%; 95% CI, 0.5–1.1%) with a CIR ratio of 0.38 (95% CI 0.19–0.6).
When a negative cytology result was added to a negative HPV result,
the 3-year CIR for CIN3+ (0.3%; 95% CI, 0.1–0.6%) was identical to that
in HPV negative women.
Detection of disease in women of different ages
To determine the impact of initiating HPV screening at different
ages, we compared the prevalence of HPV positivity and cytological ab-
normalities, as well as the 3-year cumulative detection rate of CIN3+
(or CIN2+) by age group, Table 1. The prevalence of HPV positivity
(14 pooled genotypes) was almost twice as high in women 25–29
years (21.1%; 95% CI: 20.1–22.1%) as in women 30–39 years (11.6%;
95% CI: 11.0–12.2%). HPV16/18 positivity and cytological abnormalities
were also highest inwomen 25–29 years. Althoughwomen 25–29 years
accounted for only 16.3% of all study subjects, 35.8% (95% CI; 31.9–
39.8%) and 34.3% (95% CI; 29.3–39.6%) of CIN2+ and CIN3+, respec-
tively, occurred in this age group. More cases were identiﬁed in
women 25–29 years than in women ≥40 years. In the 25–29 year age
groupmore than half ofwomenwith CIN2+(or CIN3+)had a negative
cytology result.
Comparing different screening strategies
Of the three screening strategies thatwere evaluated,HPVprimary in
women ≥25 years had the highest adjusted sensitivity over 3 years
(76.1%; 95% CI: 70.3–81.8%) for the detection of CIN3+, Table 2. For
comparison, the adjusted sensitivity of cytology for CIN3+ was 47.8%
(95% CI; 41.6–54.1%) and that of the hybrid strategy was 61.7% (95%
CI: 56.0–67.5%). In women≥25 years, cytology had the highest speciﬁc-
ity for CIN3+(97.1%; 95% CI: 96.9–97.2%) andHPVprimaryhad the low-
est speciﬁcity (93.5%; 95% CI: 93.3–93.8%). The hybrid strategy had a
speciﬁcity intermediate between the other two strategies. Similar
results were found using a CIN2+ endpoint. In women ≥30 years the
hybrid strategy and HPV primary had similar sensitivities and both
were higher than cytology for the detection of CIN3+ (or CIN2+). In
women ≥30 years cytology had a higher speciﬁcity for CIN2+ or
CIN3+ than did either the hybrid strategy or HPV primary, which had
similar speciﬁcities. Positive and negative predictive values, as well as
positive and negative likelihood ratios are also shown in Table 2. Of
note, HPV primary had a signiﬁcantly higher negative predictive value
(NPV) than cytology.
In women≥25 years cytology detected 179 (95% CI: 152–206) cases
of CIN3+: 143 (95% CI: 119–167) at baseline and 36 (95% CI: 25–49)
during follow-up, Table 3. Cytology required the fewest colposcopies
overall and the fewest colposcopies to detect a single case of CIN3+.
The hybrid strategy required almost twice the number of screening
tests as cytology, but detected 61 more cases of CIN3+ because HPV-
positive, cytology-negativewomenwere retested in 1 year and referred
to colposcopy if either test was abnormal. At year 1, 50% of HPV-
positive, cytology-negative women had an abnormal test result and
underwent colposcopy. The hybrid strategy resulted in an increase in
the number of colposcopies (60.1% compared to cytology) and an in-
crease in the number of colposcopies per case of CIN3+ detected to
12.9 (95% CI: 11.5-14.8). Similar results were seen using CIN2+ as the
endpoint.
In women≥25 yearsHPV primary detectedmore CIN3+ than either
of the other strategies, including the hybrid strategy. It detected 37.8%
more cases of CIN3+ (197; 95% CI: 169–226) at baseline compared
with either cytology or hybrid strategy (143; 95% CI: 119–167 for
both). In total, HPV primary identiﬁed 64.2% more CIN3+ (294; 95%
CI: 260–325) than cytology (179; 95% CI: 152–206) and 22.5% more
CIN3+ than the hybrid strategy (240; 95% CI; 2069–270). HPV primary
resulted in an increase in the number of colposcopies compared with
the hybrid strategy, but the number of colposcopies per case of CIN3+
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women ≥30 years, the differences between cytology and HPV primary
observed in women ≥25 years remained, but many of the differences
between the hybrid strategy and HPV primary were diminished. Both
the hybrid strategy and HPV primary identiﬁed almost the same total
number of CIN3+ in women ≥30 years and required a similar number
of colposcopies. However the increase in the number of cases of CIN3+
identiﬁed at baseline by primary HPV and the higher number of screen-
ing tests with the hybrid strategy persisted.
Discussion
Numerous cross-sectional and prospective screening trials have doc-
umented that cervical cancer screening strategies incorporating molec-
ular testing for HPV are more sensitive than cytological screening [2,9].
There are three ways that HPV testing can be incorporated into screen-
ing: as a triage for ASC-US cytology, testing all women with both HPV
and cervical cytology (e.g., “cotesting”), and HPV primary screening
in which HPV is utilized alone [3,5,9,19]. Cotesting requires moreFig. 1. A: CONSORT Diagram of ﬂow of patients through the study. B: CONSOscreening tests than HPV primary screening and interpretation of
screening results is also somewhat more complicated since all women
have two test results that must be taken into account. Recently a num-
ber of prospective randomized screening trials, primarily from Europe,
have shown that cotesting offers minimal increased protection against
the subsequent development of cervical disease compared to HPV pri-
mary screening [9,10,20,21]. Similar conclusions have been reached in
long-term follow-up studies of women enrolled in Kaiser Permanente
of Portland, Oregon and Northern California [22,23]. After 5 years of
follow-up, the cumulative probability of CIN3+ was 0.17% (95% CI;
0.11–0.28%) in HPV-negative women and 0.16% (95% CI; 0.06–0.39%)
in women with negative results for both cytology and HPV in Kaiser
Permanente, Northern California [23]. Based on these studies and cost-
effectiveness modeling analyses, both Australia and the Netherlands
have decided to adopt HPV primary screening for their national cervical
cancer prevention programs. [7,8]
ATHENA is the ﬁrst large, U.S. prospective screening study of HPV
primary screening and the results conﬁrm both that HPV primary
screening increases sensitivity when compared to cytology and thatRT Diagram showing at what point patients were diagnosed with CIN2+.
Fig. 1 (continued).
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ment of CIN2+ or CIN3+ compared to HPV primary screening. The
results of the current analyses showed thatHPVprimary screening, com-
pared to cytology, provided a 28.3% increase in sensitivity for CIN3+ in
women ≥25 years and a 24.3% increase in women ≥30 years. After 3
years of follow-up, the CIR of CIN3+ in cytology-negative women was
more than twice that of HPV-negative women and the CIR in HPV-
negative women was comparable to those who were both HPV and
cytology-negative.
In the current study, the reason why HPV primary detected more
CIN3+ in women ≥25 years is that with the hybrid strategy women
25–29 years were screened using cytology and only women ≥30 years
had the added sensitivity of HPV testing. In addition, about half of all
CIN3+ lesions were HPV16/18 positive and would be referred to col-
poscopy with HPV primary. However, with the hybrid strategy, HPV16/
18 positive women do not undergo immediate colposcopy and are
deferred to cotesting in 12 months allowing a substantial number to
be lost to follow up. It should be emphasized that current U.S. screening
recommendations do not endorse cotesting inwomen25–29 years. This
is because guideline groupswere concerned that the high prevalence of
HPV in this age groupwould result in unnecessary colposcopies and the
detection of clinically unimportant CIN2 lesions. However, we found
both a substantial burden of CIN3+ in women 25–29 years and also,
as previously reported from the United Kingdom, that cytology was
insensitive in this age group [24]. Additional studies have shown that
the relative sensitivity of HPV testing versus cytology is higher in
women younger than 30 or 35 years compared to olderwomen [25–27].
Screening guidelines attempt to balance the beneﬁts of detecting
CIN3+ with the “harms” of overscreening [3,28]. A potential harm of
overscreening is the detection of transientHPV infections that can result
in patient anxiety and unnecessary colposcopies [3,19,28]. In ATHENA
10.5%ofwomen≥25 yearswereHPV-positive. Thismeans that the ben-
eﬁts of using HPV would be outweighed by excess colposcopies unless
some form of triage is used to reduce the number of women with clini-
cally unimportant HPV infections referred to colposcopy. The most
obvious triage approaches are cytology and HPV16/18 genotyping,
both of which have been discussedwidely in the literature and incorpo-
rated into U.S. guidelines for cotesting [3,5,9,21,25]. Our HPV primary
strategy incorporates both genotyping forHPV16/18 and reﬂex cytology
for women positive for other HPV genotypes to determine who needs
colposcopy. Although HPV primary reduces the number of women un-
dergoing colposcopy compared to performing colposcopy in all HPV-positive women, it still results in a signiﬁcant increase in the number
of colposcopies compared to either cytology or the hybrid strategy.
Compared to cytology, HPV primary almost doubles the number of
colposcopies that would be performed in women ≥25 years and it
also signiﬁcantly increases the number compared to the hybrid strategy
in women≥25 years but not≥30 years. However, becauseHPV primary
detects signiﬁcantlymore CIN3+ (and CIN2+) than cytology, the num-
ber of colposcopies required to detect a single CIN3+ only increases
from 10.1 (95% CI; 8.6–12.2%) to 13.1 (95% CI; 11.5–15.2%). The number
of colposcopies required to detect a single case of CIN3+ with HPV
primary is not increased compared to the hybrid strategy, which is the
preferred screening approach in the U.S. [3,28].
ATHENA has both strengths and limitations. Strengths include num-
ber of participants, rigorous disease ascertainment, and veriﬁcation bias
adjustment. Limitations include only 3 years of follow-up with a rela-
tively high loss to follow-up rate and with a study design that exited
women with CIN2+ at baseline. Therefore the outcome if these
CIN2+ had not been treated is unknown. Other studies have found
that approximately 20% of untreated CIN2 regresses after one year and
60% after three years [29,30]. However, CIN3 infrequently regresses in
this time frame which is why we have focused on the CIN3+ data
[21]. Other limitations are that the study had organized follow-up and
it is unclear how the screening strategies would perform in the U.S.
where screening is opportunistic, that only one type of HPV test was
evaluated, and that the study is underpowered to use cervical cancer
as an endpoint.We also are unable to tell what proportion of CIN3+de-
tected during follow-up was missed by baseline colposcopy and what
proportion represents incident lesions.
In summary, ATHENA is the ﬁrst prospective U.S. screening study to
evaluate the performance of HPV primary screening. The results support
the use of HPV primary screening with triage of HPV-positive women
using a combination of genotyping for HPV 16/18 and reﬂex cytology
beginning at age 25 years. Screening with HPV primary in women ≥25
years is signiﬁcantly more sensitive for the detection of CIN3+ than
either cytology or the hybrid strategy, the two strategies supported by
current guidelines. The increase in sensitivity is associatedwith a signif-
icant increase in the number of colposcopies compared to either cytolo-
gy or the hybrid strategy but the number of colposcopies required to
detect a case of CIN3 + is the same as with the hybrid strategy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2014.11.076.
Author contributions
Dr. Thomas Wright had full access to all of the data in the study and
takes responsibility for the integrity of the data and the accuracy of the
data analysis. Drs. Wright and Behrens contributed equally to the man-
uscript. Drs. Stoler, Sharma, Zhang and Teresa Wright provided critical
guidance for the manuscript development.
Study concept and design: Thomas Wright, Mark Stoler, Catherine
Behrens, Teresa Wright.
Acquisition of data: Thomas Wright, Mark Stoler, Catherine Behrens.
Analysis and interpretation of data: Catherine Behrens, Abha Sharma,
Guili Zhang, Thomas Wright.
Drafting of the manuscript: Thomas Wright, Catherine Behrens.
Critical revision of the manuscript for important intellectual content:
Thomas Wright, Catherine Behrens, Teresa Wright.
Statistical analysis: Abha Sharma, Guili Zhang.
Administrative, technical, and material support: Roche Molecular
Systems.
Conﬂict of interest statement
Dr. Thomas C. Wright, Jr is a consultant and speaker for Roche Molecular Systems, BD
Diagnostics, and GenProbe-Hologic. He is a consultant to Cepheid. Dr. Mark H. Stoler is a
consultant and speaker for Roche Molecular Systems and GenProbe-Hologic. He is a
consultant to BD Diagnostics and Cepheid. Drs. Behrens, Sharma, Zhang are employed by
Roche Molecular Systems. Dr. Teresa Wright is employed by Genentech.
Fig. 2. Veriﬁcation bias-adjusted (VBA) cumulative incidence of consensus pathology cervical intraepithelial neoplasia 2+ (CIN2+) (A) and CIN3+ (B) during 3 years of follow-up
stratiﬁed by baseline human papillomavirus (HPV) status. Red solid line, HPV-16 positive; blue solid line, HPV-18 positive; green solid line, 12 other HPV genotypes positive; black dotted
line, HPV-negative.
194 T.C. Wright et al. / Gynecologic Oncology 136 (2015) 189–197Funding/support
Supported by Roche Molecular Systems, Pleasanton, CA.
Role of the sponsor
RocheMolecular Systems, Pleasanton, CAwas involved in all aspects
of the design and conduct of the study; collection, management,
analysis, and interpretation of the data. Catherine Behrens and Abha
Sharma who are Roche employees were integral to the preparation of
the manuscript and the sponsor reviewed the ﬁnal manuscript.
Previous presentations of parts of the data
Society of Gynecologic Oncology Annual Meeting, March 2013,
Los Angeles, CA; EUROGIN, November 2013, Florence, Italy; Society of
Gynecologic Oncology Annual Meeting, March 2014, Tampa, FL.Fig. 3. Veriﬁcation bias-adjusted (VBA) 3-year cumulative incidence rates of consensus path
combinations of baseline cervical cytology and HPV results. Note the x-axis is logarithmic.Acknowledgments
We would also like to acknowledge the contribution of Philip
Castle, PhD, Global Cancer Initiative, Chestertown, MD for the advice
in the design of the ATHENA study. Janet Kornegay, PhD, Sean Boyle,
BS, Rita Sun, MS, Christoph Majewski, PhD and Mark Krevolin, PhD,
Roche Molecular Systems contributed to the development of the
cobas HPV Test. Poh-Sin Yap, PhD and Shagufta Aslam, PhD provided
statistical assistance in the analysis of data. The following investigators
participated in the ATHENA study:
Laboratory testing sites
LabCorp, Burlington, NC: B.A. Body; Roche Molecular Systems,
Pleasanton, CA, A. Butcher; DCL Medical Laboratories, Indianapolis, IN, C.
Eisenhut; Scott & White Memorial Hospital, Temple, TX, A. Rao; TriCore
Reference Laboratories, Albuquerque, NM, S. Young.ology cervical intraepithelial neoplasia 2+ (CIN2+) and CIN3+ stratiﬁed by different
Table 2
Adjusted performance of different screening strategies for the detection of cervical disease
at baseline and through Year 3.
Strategy Performance measure
(95% CI)
CIN2+ CIN3+
Women ≥25 years
Cytology Sensitivity 40.6 (36.1–45.1) 47.8 (41.6–54.1)
Speciﬁcity 97.3 (97.1–97.5) 97.1 (96.9–97.2)
Positive Predictive Value 24.8 (22.3–27.4) 17.0 (14.7–19.2)
Negative Predictive Value 98.7 (98.5–98.9) 99.3 (99.2–99.5)
Positive Likelihood Ratio 15.1 (13.7–16.7) 16.3 (14.6–18.1)
Negative Likelihood Ratio 0.6 (0.6–0.6) 0.5 (0.5–0.6)
Hybrid strategy Sensitivity 55.5 (50.4–60.5) 61.7 (56.0–67.5)
Speciﬁcity 95.0 (94.8–95.2) 94.6 (94.4–94.8)
Positive Predictive Value 19.5 (17.6–21.4) 12.6 (11.2–13.9)
Negative Predictive Value 99.0 (98.8–99.2) 99.5 (99.4–99.6)
Positive Likelihood Ratio 11.1 (10.3–11.9) 11.4 (10.6–12.4)
Negative Likelihood Ratio 0.5 (0.4–0.5) 0.4 (0.4–0.5)
HPV primary Sensitivity 69.1 (63.7–74.4) 76.1 (70.3–81.8)
Speciﬁcity 94.0 (93.8–94.3) 93.5 (93.3–93.8)
Positive Predictive Value 20.2 (18.3–22.0) 12.9 (11.6–14.2)
Negative Predictive Value 99.3 (99.1–99.5) 99.7 (99.6–99.8)
Positive Likelihood Ratio 11.5 (10.9–12.2) 11.8 (11.1–12.5)
Negative Likelihood Ratio 0.3 (0.3–0.4) 0.3 (0.2–0.3)
Women ≥30 years
Cytology Sensitivity 40.3 (34.6–46.0) 48.0 (40.6–55.4)
Speciﬁcity 97.9 (97.7–98.0) 97.7 (97.5–97.8)
Positive Predictive Value 23.9 (21.0–26.8) 16.7 (13.9–19.5)
Negative Predictive Value 99.0 (98.8–99.2) 99.5 (99.4–99.6)
Positive Likelihood Ratio 18.8 (16.6–21.2) 20.6 (18.0–23.5)
Negative Likelihood Ratio 0.6 (0.6–0.7) 0.5 (0.5–0.6)
Hybrid strategy Sensitivity 63.4 (56.7–70.1) 69.3 (61.7–76.9)
Speciﬁcity 95.1 (94.8–95.3) 94.7 (94.5–95.0)
Positive Predictive Value 17.8 (15.8–19.8) 11.4 (9.8–13.0)
Negative Predictive Value 99.4 (99.2–99.5) 99.7 (99.6–99.8)
Positive Likelihood Ratio 12.9 (11.9–14.0) 13.2 (12.1–14.4)
Negative Likelihood Ratio 0.4 (0.4–0.4) 0.3 (0.3–0.4)
HPV primary Sensitivity 64.8 (58.4–71.1) 72.3 (65.0–79.6)
Speciﬁcity 95.2 (95.0–95.5) 94.9 (94.6–95.1)
Positive Predictive Value 18.5 (16.4–20.6) 12.1 (10.4–13.8)
Negative Predictive Value 99.4 (99.2–99.5) 99.7 (99.6–99.8)
Positive Likelihood Ratio 13.5 (12.5–14.6) 14.1 (13.0–15.3)
Negative Likelihood Ratio 0.4 (0.3–0.4) 0.3 (0.3–0.4)
Table 1
Impact of age on HPV status and CIN2+ and CIN3+.
25–29 years 30–39 years 40–49 years ≥50 years Total
Baseline result
Number
(% of row; 95% CI)
6647
(16.3%; 15.9–16.6%)
12,248
(29.9%; 29.5–30.4%)
11,689
(28.6%; 28.1–29.0%)
10,317
(25.2%; 24.8–25.6%)
40,901
hrHPV (+)
(% of age group; 95% CI)
1403
(21.1%; 20.1–22.1%)
1419
(11.6%; 11.0–12.2%)
830
(7.1%; 6.–7.6%)
623
(6.0%; 5.6–6.5%)
4275
HPV 16/18 (+)
(% of age group; 95% CI)
464
(7.0%; 6.4–7.6%)
401
(3.3%; 3.0–3.6%)
181
(1.5%; 1.3–1.8%)
121
(1.2%; 1.0–1.4%)
1167
Cytology ≥ ASCUS
(% of age group; 95% CI)
651
(9.8%; 9.1–10.5%)
849
(6.9%; 6.5–7.4%)
727
(6.2%; 5.8–6.7%)
390
(3.8%; 3.4–4.2%)
2617
Cumulative detection of cervical disease at baseline and through year 3
Number CIN2
(% of row; 95% CI)
91
(37.9%; 31.8–44.4%)
85
(35.4%; 29.4–41.8%)
44
(18.3%; 13.6–23.8%)
20
(8.3%; 5.2–12.6%)
240
Number CIN2+
(% of row; 95% CI)
210
(35.8%; 31.9–39.8%)
225
(38.3%; 34.4–42.4%)
101
(17.2%; 14.2–20.5%)
51
(8.7%; 6.5–11.3%)
587
% Cytology ≥ ASCUS
(95% CI) in CIN2+
42.9% (36.1–49.8%) 49.3%
(42.6–56.1%)
59.4%
(49.2–69.1%)
47.1%
(32.9–61.5%)
% 16/18 HPV (+)
(95% CI) in CIN2+
47.6%
(40.7–54.6%)
47.1%
(40.4–53.9%)
30.7%
(21.9–40.7%)
29.4%
(17.5–43.8%)
Number CIN3+
(% of row; 95% CI)
119
(34.3%; 29.3–39.6%)
140
(40.3%; 35.1–45.7%)
57
(16.4%; 12.7–20.8%)
31
(8.9%; 6.2–12.4%)
347
% Cytology ≥ ASCUS
(95% CI) in CIN3+
43.7%
(34.6–53.1%)
55.0%
(46.4–63.4%)
59.6%
(45.8–72.4%)
64.5%
(45.4–80.8%)
% 16/18 HPV (+)
(95% CI) in CIN3+
57.1%
(47.7–66.2%)
56.4%
(47.8–64.8%)
43.9%
(30.7–57.6%)
45.2%
(27.3–64.0%)
The conﬁdence interval calculation is based on exact conﬁdence interval for proportion.
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Research Associates, Corpus Christi, TX, C. Eubank; Advanced Clinical
Concepts, West Reading, PA, S. Fehnel; Miami Research Associates,
Miami, FL, R. Feldman; Center for Women's Health of Lansdale, Lansdale,
PA, R. Filosa; Blue Skies Center forWomen, Colorado Springs, CO, S. Fowler;
Visions Clinical Research, Tucson, AZ, C. Goldberg; Impact Clinical Trials,
Las Vegas, NV, R. Groom; Physicians' Research Options, Lakewood, CO,
J. Grube; Four Rivers Clinical Research, Paducah, KY, P. Grumley;Medical
Network for Education and Research, Decatur, GA, P. Hadley; Women's
Health Research, Phoenix, AZ,M. Harris; Impact Clinical Trials, Los Angeles,
CA, L. Hazan; HWC Women's Research Center, Englewood, OH, J. Huey;
Texas Medical Center, Houston, TX, M. Jacobs; Mobile OB/GYN, Mobile,
AL, S. Kleinpeter; Altus Research, Lake Worth, FL, S. Lederman; Tacoma
Women's Specialist, Tacoma, WA, J. Lenihan, Jr; Phoenix OB-GYN Associa-
tion, Moorestown, NJ, B. Levine; The Woman's Clinic, Boise, ID, K. Lowder;
Impact Clinical Trials, Los Angeles, CA, N. Lurvey; eCast Corporation, North
Charleston, SC, J. Martin, Jr; State of Franklin Healthcare Associates
Research, Johnson City, TN, R. McDavid; Quality of Life Medical & Research
Center, Tucson, AZ, J. McGettigan; Eastern Carolina Women's Center, New
Bern, NC, J. Michelson; Tidewater Clinical Research, Virginia Beach, VA, F.
Morgan; St. John's Center for Clinical Research, Jacksonville, FL, R. Myers;
M & O Clinical Research, Ft. Lauderdale, FL, K. Osman; Lyndhurst Gyneco-
logic Associates, PA, Winston-Salem, NC, R. Parker, Jr; Enterprise Women's
Center, Enterprise, AL, J. Pollard; Salt Lake Research, Salt Lake City,
UT, A. Rappleye; Women's Health Care at Frost Street, San Diego, CA,
R. Reagan; Atlanta North Gynecology Center for Research, Roswell, GA,
Table 3
Detection of cervical disease using different screening strategies and the number of screening tests and colposcopies that each strategy requires.
Strategy Number of detected casesa (95% CI) No. missed
cases
No. screening tests
(95% CI)
No. colposcopies
(95% CI)
No. colposcopies to
detect 1 case
(95% CI)
Total Detected at
baseline
Detected years
1–3
≥25 years
CIN2+ Cytology 270
(239–303)
215
(187–245)
55
(41–70)
317
(282–350)
45,166
(44,931–45,392)
1934
(1809–2061)
7.1
(6.4–8.0)
Hybrid strategy 384
(347–421)
215
(187–245)
169
(145–193)
203
(178–230)
82,994
(82,634–83,397)
3097
(2948–3264)
8.1
(7.4–8.9)
HPV primary 471b,c
(430–514)
283b,c
(250–318)
188
(164–215)
116d,e
(97–136)
52,651b,e
(52,249–53,111)
3767b,c
(3617–3962)
8.0b
(7.4–8.8)
CIN3+ Cytology 179
(152–206)
143
(119–167)
36
(25–49)
168
(144–194)
45,166
(44,931–45,392)
1934
(1809–2061)
10.8
(9.4–12.6)
Hybrid strategy 240
(209–270)
143
(119–167)
97
(79–115)
107
(89–126)
82,994
(82,634–83,397)
3097
(2948–3264)
12.9
(11.5–14.8)
HPV primary 294b,c
(260–325)
197b,c
(169–226)
97
(78–115)
53d,e
(42–66)
52,651b,e
(52,249–53,111)
3769b,c
(3617–3962)
12.8b
(11.7–14.5)
≥30 years
CIN2+ Cytology 185
(158–213)
144
(121–168)
41
(29–54)
192
(164–221)
37,312
(37,077–37,574)
1294
(1197–1390)
7.0
(6.1–8.1)
Hybrid strategy 299
(267–331)
144
(121–168)
155
(133–178)
78
(64–94)
75,140
(74,684–75,614)
2457
(2316–2607)
8.2
(7.4–9.2)
Primary HPV 299b
(266–332)
178b,c
(152–205)
121
(101–143)
78d
(63–94)
42,425b,e
(42,030–42,847)
2522b,c
(2376–2667)
8.4b
(7.6–9.4)
CIN3+ Cytology 128
(105–152)
106
(87–127)
22
(13–31)
100
(82–121)
37,321
(37,077–37,574)
1294
(1197–1390)
10.1
(8.6–12.2)
Hybrid strategy 189
(163–215)
106
(87–127)
83
(67–99)
39
(30–49)
75,140
(74,684–75,614)
2457
(2316–2607)
13.0
(11.5–15.0)
Primary HPV 192b
(165–218)
136b,c
(113–160)
56
(42–71)
36d
(27–48)
42,425b,e
(42,030–42,847)
2522b,c
(2376–2667)
13.1b
(11.5–15.2)
CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.
a This analysis utilizes crude numbers of detected cases as opposed to veriﬁcation bias adjusted numbers.
b Signiﬁcantly higher than Cytology only (p b 0.05).
c Signiﬁcantly higher than Hybrid strategy (p b 0.05).
d Signiﬁcantly lower than Cytology only (p b 0.05).
e Signiﬁcantly lower than Hybrid strategy (p b 0.05).
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K.Waldrep; Fellows Research Alliance, Savannah, GA,D.Walland; Fellows
Research Alliance, Hilton Head, SC, D. Walland; Women's Care Florida,
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W. Wilson; Precision Trials, Phoenix, AZ, S. Wininger; Yassear Clinical
Research, Carmichael, CA, S. Yassear.References
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